Mr. Dabney concludes, "It has certainly been a long road to get here, but we are here no doubt. To see things coming together as they are, is very exciting for us of course.
With the dividend almost completed, more new products being released, preparations for the larger capital raise, progressing our formal FDA drug development initiatives and proposed NASDAQ uplisting, things are certainly on the move, in the right direction.
On the dividend, we have submitted some additional requested documentation to FINRA; we hope this to be the last and then we can begin the dividend share distribution and proceed to file for a new additional trading symbol to accommodate the much larger capital raise."
News 
Market Data 
Discover 
